AFP and cancer: The survival rate of HCC is at most 5 years, which is still very low, partly because of the unsatisfactory results of conventional biomarkers (e.g., DPC, AFP and AFP-L3) that are often unable to distinguish between cancer and inflammatory diseases, such as chronic hepatitis or liver cirrhosis [126].